DIVA Laboratories Ltd
DIVA Laboratories, Ltd. engages in the development, manufacture, and sale of medical equipment and computer related devices worldwide. The company provides endo/surgical displays, a static and dynamic image for hybrid and integrated ORs applications; color and mono displays for radiology and medical imaging applications; touch displays/human machine interface products; medical and industrial case… Read more
DIVA Laboratories Ltd (4153) - Net Assets
Latest net assets as of June 2025: NT$984.76 Million TWD
Based on the latest financial reports, DIVA Laboratories Ltd (4153) has net assets worth NT$984.76 Million TWD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$1.41 Billion) and total liabilities (NT$422.17 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$984.76 Million |
| % of Total Assets | 69.99% |
| Annual Growth Rate | 3.91% |
| 5-Year Change | 6.74% |
| 10-Year Change | N/A |
| Growth Volatility | 17.71 |
DIVA Laboratories Ltd - Net Assets Trend (2017–2024)
This chart illustrates how DIVA Laboratories Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for DIVA Laboratories Ltd (2017–2024)
The table below shows the annual net assets of DIVA Laboratories Ltd from 2017 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | NT$1.06 Billion | +2.20% |
| 2023-12-31 | NT$1.03 Billion | +1.64% |
| 2022-12-31 | NT$1.02 Billion | +3.02% |
| 2021-12-31 | NT$986.42 Million | -0.25% |
| 2020-12-31 | NT$988.89 Million | -12.74% |
| 2019-12-31 | NT$1.13 Billion | -4.28% |
| 2018-12-31 | NT$1.18 Billion | +46.76% |
| 2017-12-31 | NT$806.75 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to DIVA Laboratories Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 37236800000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | NT$94.12 Million | 8.92% |
| Other Components | NT$961.38 Million | 91.08% |
| Total Equity | NT$1.06 Billion | 100.00% |
DIVA Laboratories Ltd Competitors by Market Cap
The table below lists competitors of DIVA Laboratories Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Big Sunshine Co Ltd
TW:1475
|
$25.67 Million |
|
TJ media Co. Ltd
KQ:032540
|
$25.68 Million |
|
Telomir Pharmaceuticals, Inc. Common Stock
NASDAQ:TELO
|
$25.69 Million |
|
New Delhi Television Limited
NSE:NDTV
|
$25.69 Million |
|
PT Wijaya Karya (Persero) Tbk
F:5AA
|
$25.67 Million |
|
Taiwan Name Plate Co. Ltd.
TWO:6593
|
$25.65 Million |
|
H.H.Galaxy Co., Ltd.
TWO:2949
|
$25.64 Million |
|
Green Cross Medical Science Corporation
KQ:142280
|
$25.64 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in DIVA Laboratories Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,032,802,000 to 1,055,502,000, a change of 22,700,000 (2.2%).
- Net income of 93,661,000 contributed positively to equity growth.
- Dividend payments of 73,335,000 reduced retained earnings.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$93.66 Million | +8.87% |
| Dividends Paid | NT$73.33 Million | -6.95% |
| Other Changes | NT$2.37 Million | +0.22% |
| Total Change | NT$- | 2.20% |
Book Value vs Market Value Analysis
This analysis compares DIVA Laboratories Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.90x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | NT$17.90 | NT$34.10 | x |
| 2018-12-31 | NT$19.70 | NT$34.10 | x |
| 2019-12-31 | NT$15.70 | NT$34.10 | x |
| 2020-12-31 | NT$14.86 | NT$34.10 | x |
| 2021-12-31 | NT$16.78 | NT$34.10 | x |
| 2022-12-31 | NT$17.27 | NT$34.10 | x |
| 2023-12-31 | NT$17.60 | NT$34.10 | x |
| 2024-12-31 | NT$17.99 | NT$34.10 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently DIVA Laboratories Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 8.87%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 10.86%
- • Asset Turnover: 0.66x
- • Equity Multiplier: 1.24x
- Recent ROE (8.87%) is above the historical average (0.14%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | -33.11% | -31.17% | 0.81x | 1.32x | NT$-347.82 Million |
| 2018 | 4.41% | 8.02% | 0.49x | 1.12x | NT$-66.24 Million |
| 2019 | 4.95% | 7.83% | 0.55x | 1.15x | NT$-57.28 Million |
| 2020 | 1.76% | 2.36% | 0.66x | 1.13x | NT$-81.47 Million |
| 2021 | 2.22% | 3.07% | 0.60x | 1.20x | NT$-76.79 Million |
| 2022 | 4.89% | 5.23% | 0.76x | 1.23x | NT$-51.96 Million |
| 2023 | 7.13% | 8.24% | 0.72x | 1.20x | NT$-29.66 Million |
| 2024 | 8.87% | 10.86% | 0.66x | 1.24x | NT$-11.89 Million |
Industry Comparison
This section compares DIVA Laboratories Ltd's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $400,044,167
- Average return on equity (ROE) among peers: 0.74%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| DIVA Laboratories Ltd (4153) | NT$984.76 Million | -33.11% | 0.43x | $25.67 Million |
| Bionet (1784) | $1.32 Billion | 2.02% | 0.36x | $107.18 Million |
| Kim Forest Enterprise Co., Ltd. (6645) | $32.49 Million | 0.00% | 7.10x | $20.40 Million |
| Welgene Biotech Co.Ltd. (6661) | $246.55 Million | 11.49% | 0.47x | $3.31 Million |
| Puriblood Medical Co., Ltd. (6847) | $175.40 Million | -3.06% | 0.48x | $13.28 Million |
| TFBS Bioscience Inc. (6939) | $247.95 Million | 0.12% | 0.16x | $5.40K |
| Pharmigene, Inc. (7595) | $382.22 Million | -6.13% | 0.10x | $10.10 Million |